Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes

Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebedev, Timofey, Vagapova, Elmira, Spirin, Pavel, Rubtsov, Petr, Astashkova, Olga, Mikheeva, Alesya, Sorokin, Maxim, Vladimirova, Uliana, Suntsova, Maria, Konovalov, Dmitry, Roumiantsev, Alexander, Stocking, Carol, Buzdin, Anton, Prassolov, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566230/
https://www.ncbi.nlm.nih.gov/pubmed/34556815
http://dx.doi.org/10.1038/s41388-021-02018-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566230/
https://www.ncbi.nlm.nih.gov/pubmed/34556815
http://dx.doi.org/10.1038/s41388-021-02018-7

Ejemplares similares